Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

A randomised controlled trial evaluating the effect of potassium supplementation on vascular function and the renin–angiotensin–aldosterone system

Journal of Human Hypertension volume 28, pages 333–339 (2014)Cite this article

Subjects

Abstract

There is limited evidence on the effect of potassium supplementation on the vasculature in patients at increased cardiovascular risk. Potassium increases aldosterone and there is a strong association of hyperaldosteronism with poor cardiac outcomes. We aimed to determine whether potassium supplementation has a significant medium-term effect on aldosterone levels and, if so, what the overall effect of this is on vascular function in patients at moderate cardiovascular disease risk. Forty patients at moderate cardiovascular disease risk were included in a randomised placebo-controlled crossover study. Patients were assigned to 64 mmol potassium chloride or placebo for 6 weeks. Vascular function was assessed using pulse-wave analysis including the detection of a change in augmentation index to salbutamol and nitroglycerine-induced vasodilation. There was no change in augmentation index with potassium vs placebo (25.2±1.4 vs 26.0±1.3%, respectively). Potassium improved brachial systolic blood pressure (131.8±2.2 vs 137.1±2.4 mm Hg; P=0.013), central systolic blood pressure (123.2±2.3 vs 128.4±2.3 mm Hg; P=0.011) and central diastolic blood pressure (80.3±1.3 vs 83.7±1.4 mm Hg; P=0.019). Plasma renin activity and serum aldosterone both increased with potassium (P=0.001 and P=0.048 respectively). We found that potassium supplementation had no effect on endothelial function or pulse-wave analysis. It lowered brachial systolic and central blood pressure. It was associated with increased plasma renin activity and serum aldosterone.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follman D et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled trials. JAMA 1997; 277: 1624–1632.

    Article  CAS  Google Scholar 

  2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M et al. ACC/AHA Guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2004; 110: 588–636.

    Article  Google Scholar 

  3. Macdonald JE, Struthers AD . What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004; 43: 155–161.

    Article  CAS  Google Scholar 

  4. Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012; 307: 157–164.

    Article  CAS  Google Scholar 

  5. Stewart PM . The adrenal cortex. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, Williams Textbook of Endocrinology 11th edn Saunders Elsevier: Philadelphia, 2008 pp 445–503.

    Google Scholar 

  6. Young M, Funder JW . Eplerenone but not steroid withdrawal reverses cardiac fibrosis in deoxycorticosterone/salt treated rats. Endocrinology 2004; 145: 3153–3157.

    Article  CAS  Google Scholar 

  7. Staermose S, Marwick TH, Gordon RD, Crowley D, Dowling A, Stowasser M . Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1. Hypertension 2009; 53: e31–e32.

    Article  CAS  Google Scholar 

  8. Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK . Aldosterone production and insulin resisitance in healthy adults. J Clin Endocrinol Metab 2010; 95: 1986–1990.

    Article  CAS  Google Scholar 

  9. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S et al. Hyperinsulinaemia as an independent risk factor for ischaemic heart disease. N Engl J Med 1996; 334: 952–957.

    Article  CAS  Google Scholar 

  10. He FJ, Marciniak M, Carney C, Markandu ND, Anand N, Fraser WD et al. Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors and bone turnover in mild hypertensives. Hypertension 2010; 55: 681–688.

    Article  CAS  Google Scholar 

  11. Joint British Societies. The Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl V): v1–v52.

    Google Scholar 

  12. Tiu SC, Choi CH, Shek CC, Ng YW, Chan FKW, Ng CM et al. The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Metab Endocrinol 2005; 90: 72–78.

    Article  CAS  Google Scholar 

  13. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. Case detection, diagnosis and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266–3281.

    Article  CAS  Google Scholar 

  14. Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, Maughan WL et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Circulation 1997; 95: 1827–1836.

    Article  CAS  Google Scholar 

  15. Siebenhofer A, Kemp CR, Sutton AJ, Williams B . The reproducibility of central aortic blood pressure measurements in healthy subjects using applanation tonometry and sphygmocardiography. J Hum Hypertens 1999; 13: 625–629.

    Article  CAS  Google Scholar 

  16. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998; 16: 2079–2084.

    Article  CAS  Google Scholar 

  17. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–2605.

    Article  Google Scholar 

  18. Wilkinson IB, Hall IR, MacCallum H, Mackenzie IS, McEniery CM, Van der Arend BJ et al. Pulse wave analysis—clinical evaluation of a non-invasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol 2002; 22: 147–152.

    Article  CAS  Google Scholar 

  19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

    Article  CAS  Google Scholar 

  20. Hills M, Armitage P . The two period cross-over clinical trial. Br J Clin Pharmac 1979; 8: 7–20.

    Article  CAS  Google Scholar 

  21. Najjar SS, Scuteri A, Shetty V, Wright JG, Muller DC, Fleg JL et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore longitudinal study of aging. J Am Coll Cardiol 2008; 51: 1377–1383.

    Article  Google Scholar 

  22. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50: 197–203.

    Article  CAS  Google Scholar 

  23. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Willens HJ et al. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 2005; 45: 980–985.

    Article  CAS  Google Scholar 

  24. Fang Y, Mu JJ, He LC, Wang SC, Liu ZQ . Salt loading on plasma asymmetrical dimethylarginine and the protective role of potassium supplement in normotensive salt-sensitive Asians. Hypertension 2006; 48: 724–729.

    Article  CAS  Google Scholar 

  25. Shi DC, Mu JJ, Chen ER, Ren J, Yang XL, Liu WM et al. Endothelial function evaluation in salt-sensitive normotensive and mild hypertensive subjects and effects of potassium supplementation. Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34: 38–41.

    CAS  PubMed  Google Scholar 

  26. Dluhy RG, Axelrod L, Underwood RH, Williams GH . Studies of the control of plasma aldosterone concentration in normal man. J Clin Invest 1972; 51: 1950–1957.

    Article  CAS  Google Scholar 

  27. Brunner HR, Baer L, Sealey JE, Ledingham JGG, Laragh JH . The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest 1970; 49: 2128–2138.

    Article  CAS  Google Scholar 

  28. Chen Q, Turban S, Miller ER, Appel LJ . The effects of dietary patterns on plasma renin activity: results from the Dietary Approaches to Stop Hypertension trial. J Hum Hypertens 2012; 26: 664–669.

    Article  CAS  Google Scholar 

  29. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–771.

    Article  CAS  Google Scholar 

  30. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.

    Article  CAS  Google Scholar 

  31. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R et al. Cardiovascular and cerebrovascular comorbidities of hypokalaemic and normokalaemic primary aldosteronism: results of the German Conn’s registry. J Clin Endocrinol Metab 2009; 94: 1125–1130.

    Article  CAS  Google Scholar 

  32. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H et al. Modification of mineralocorticoid receptor function by RacI GTPase: implications in proteinuric kidney disease. Nat Med 2008; 14: 1370–1376.

    Article  CAS  Google Scholar 

  33. Chamarthi B, Williams JS, Williams GH . A mechanism for salt-sensitive hypertension: abnormal dietary sodium-mediated vascular response to angiotensin-II. J Hypertens 2010; 28: 1020–1026.

    Article  CAS  Google Scholar 

  34. Food Standards Agency. National Centre for Societal Research. An assessment of dietary sodium levels among adults (aged 19–64) in the UK general population in 2008, based on analysis of dietary sodium in 24 h urine samples. Accessed November 2011 http://www.food.gov.uk/multimedia/pdfs/08sodiumreport.pdf.

  35. Johansson L, Solvoll K, Bjornboe DE, Drevon CA . Under- and over-reporting of energy intake related to weight status and lifestyle in a nationwide sample. Am J Clin Nutr 1998; 68: 266–275.

    Article  CAS  Google Scholar 

  36. Adrogue HJ, Madias ME . Sodium and potassium in the pathogenesis of hypertension. N Engl J Med 2007; 356: 1966–1978.

    Article  CAS  Google Scholar 

  37. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM et al. Aclinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117–1124.

    Article  CAS  Google Scholar 

  38. Turban S, Miller ER, Ange B, Appel LJ . Racial differences in urinary potassium excretion. J Am Soc Nephrol 2008; 19: 1396–1402.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK

    U M Graham, D R McCance & K R Mullan

  2. Centre for Public Health, Queen’s University, Belfast, UK

    I S Young

Authors
  1. U M Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D R McCance
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I S Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K R Mullan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U M Graham.

Ethics declarations

Competing interests

The authors declare no conflict of intrest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Graham, U., McCance, D., Young, I. et al. A randomised controlled trial evaluating the effect of potassium supplementation on vascular function and the renin–angiotensin–aldosterone system. J Hum Hypertens 28, 333–339 (2014). https://doi.org/10.1038/jhh.2013.89

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2013.89

Keywords

This article is cited by

Search

Advanced search

Quick links